Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Evorpacept + Trastuzumab deruxtecan|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Evorpacept||ALX-148|ALX 148|ALX148||CD47 Antibody 29 Immune Checkpoint Inhibitor 146||Evorpacept (ALX148) is a chimeric protein consisting of the Fc region of immunoglobulin fused to the CD47 SIRPa-binding domain, that blocks the ability of CD47 to bind SIRPa on macrophages thereby promoting phagocytosis of tumor cells (PMID: 28286286), and may also stimulate cytotoxic T-cells (PMID: 29873856).|
|Trastuzumab deruxtecan||Enhertu||DS-8201|DS8201a|T-DXd|DS-8201|fam-trastuzumab deruxtecan-nxki||HER2 (ERBB2) Antibody 63 HER2 (ERBB2) Antibody-Drug Conjugate 24||Enhertu (trastuzumab deruxtecan) is an antibody-drug conjugate (ADC) comprising an anti-ERBB2 (HER2) antibody linked to a derivative of the topoisomerase inhibitor DX-8951, which delivers the cytotoxic agent to ERBB2 (HER2)-expressing tumor cells, potentially resulting in decreased growth of tumors, including tumors with low ERBB2 (HER2) expression (PMID: 27026201). Enhertu (fam-trastuzumab deruxtecan-nxki) is FDA approved for use in patients with ERBB2 (HER2)-positive breast cancer who have received two or more anti-HER2 therapies previously, in patients with ERBB2 (HER2)-low (IHC 1+ or IHC 2+/ISH -) breast cancer received prior chemotherapy, in patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received prior trastuzumab-based therapy, and in patients with non-small cell lung cancer harboring ERBB2 (HER2) activating mutations who have received prior systemic therapy (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05868226||Phase I||Evorpacept + Trastuzumab deruxtecan||PRE-I-SPY Phase I/Ib Program (PRE-I-SPY-PI)||Recruiting||USA||0|